Advantage & Core Benefits
- Much higher tolerability with reduced toxicity.
- Synergetic effects with radiation therapy confirmed by Gemcitabine, PARP, CDK4/6 inhibitors.
- Prodrugs of three classic chemotherapy compounds are registered-patent protected.
Background & Technology
Although chemotherapies are commonly prescribed to kinds of tumors, severe adverse effects owing to the toxicity to normal dividing cells limit the doses and efficacies. And those drugs cannot reach hypoxic regions of tumor, which could be one of the reasons that cancers acquire drug resistance, abilities of invasion and metastasis.
The novel hypoxia-activated prodrugs are engineered with nitro-imidazole derivative, which are designed to seal the toxicity in normoxic condition, selectively distribute to hypoxic region of tumor and are activated.
Data
- 5-FU, Doxorubicin(Dox), Gemcitabine(Gem), Niraparib(PARP), Panobinostat/Entinostat(HDAC), Crizotinib /Ceritinib(ALK/ROS), Cobimetinib(MEK), Dabrafenib/Vemurafenib(BRAF), Palbociclib/ribociclib(CDK) have shown to be applicable.
- Combination effect with Radiation Therapy was confirmed by Gem(Fig), and other compounds.
Patent
Dox, Gem, 5-FU product registered: 9655975(US), 2816036 (EP), 5676020 (JP)
Radiation combination therapy: WO2023/120331
Researchers
Dr. Yutaka Ikeda and Dr. Yukio Nagasaki (University of Tsukuba)
Expectations
We are seeking companies who are interested in in-licensing and commercialization.
Other than HAPs already created, applicability study for other molecules are welcome.
Samples are available under material transfer agreement.
Product No:KJ-02445